news

Pharmacopeial Discussion Group releases major particulate contamination update

7
SHARES

Revisions to the harmonised general chapter “Particulate Contamination (Q-09)” aim to improve pharmaceutical drug development.

Particulate Contamination (Q-09) Pharmacopeial Discussion Group (PDG)

Testing procedures for sub-visible particulate matter in all injectable products are being standardised in a new update from the Pharmacopeial Discussion Group (PDG).

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The Group’s revised harmonised general chapter “Particulate Contamination (Q-09)” is now available, following sign-off on 2 May.

The PDG comprises of the European Pharmacopoeia (Ph. Eur.), the Indian Pharmacopoeia Commission (IPC), the Japanese Pharmacopoeia (JP) and the United States Pharmacopeia (USP). 

This new version of the chapter provides a “more robust and adaptable” standardisation process for testing procedures for sub-visible particulate matter in all injectable products in these regions, according to the European Directorate for the Quality of Medicines & HealthCare (EDQM).

Key changes to the general chapter include: 

  • Definition clarification 
  • Guidance on sample preparation, especially for formulations with a volume of 25 mL or less 
  • Method 1 (light obscuration particle count test) updates 
  • Method 2 (microscopic particle count test) updates.

This new version of the [Particulate Contamination (Q-09)] chapter provides a more robust and adaptable standardisation process for testing procedures for sub-visible particulate matter in all injectable products in these regions”

For example, while the revision noted that Method 1 is preferable to use when examining the parenteral preparation for sub-visible particles, “not all parenteral preparations can be examined directly for sub-visible particles by one or both of these methods”.

However, “when Method 1 is not applicable, eg, in case of preparations having reduced clarity or increased viscosity (some emulsions, suspensions, colloids, and liposomal preparations are examples)”, testing via Method 2 should be used.

Yet since the methods measure different characteristics, “the two methods cannot be considered interchangeable”, according to the PDG.

Publication of “Particulate Contamination (Q-09)” chapter revision

The corresponding texts are scheduled for publication by each member of the PDG in:

  • July 2025 (USP text <788> with <787> to be omitted in the future)
  • April 2026 (JP general test <07>)
  • July 2026 (Ph. Eur. general chapter 9.19).

Having joining in 2023, as the PDG’s newest member, the IPC will implement the text at a later stage than other members.

As part of their collaborative work to improve global quality standards, the European and Japanese Pharmacopoeias last year partnered to harmonise pharmacopoeial standards for active substance and medicinal product monographs.

Share via
Share via